摘要
目的观察预防性使用替普瑞酮对实验性门脉高压大鼠胃黏膜的保护作用。方法128只大鼠均分为正常对照组、正常干预组、单纯造模组和造模干预组,后2组腹腔注射硫代乙酰胺制作门脉高压大鼠模型。正常干预组和造模干预组同步给予口服替普瑞酮治疗。观察各组在8、12、16、20周末胃凝胶黏液层厚度和胃黏膜损伤指数。结果门脉高压大鼠胃凝胶层厚度明显下降,胃黏膜损伤指数增高。造模干预组治疗16周和20周后胃凝胶层厚度分别为(34.89±9.84)μm和(32.34±4.24)μm,明显高于单纯造模组[(20.24±8.27)μm和(15.52±5.92)μm,P<0.01];胃黏膜损伤指数分别为13.8±6.5和20.5±4.6,与单纯造模组(30.7±8.6和35.6±9.5)比较差异有显著性(P<0.01)。结论替普瑞酮对门脉高压胃黏膜可能具有一定的保护作用。
Objective To investigate the gastric mucosal protection effect of Teprenone in portal hypertensive rats. Methods Experimental portal hypertensive rat models were established by injecting Thioacetamide intraperitoneally. One hundred and twenty eight rats were divided into normal control group, normal therapy group, model control group and model therapy group. Both normal therapy group and model therapy group were treated by Teprenone orally. The thickness of gastric gelatinous mucus and gastric ulcer index (UI) in the four groups were detected after 8,12,16,20 weeks. Results The thickness of gastric gelatinous mucus was decreased and gastric UI were increased in portal hypertensive rats. After 16 weeks and 20 weeks, the thickness of gastric gelatinous mucus in the model therapy group was higher than those in model control group respectively[(34.89±9.84 )μm vs (20.24±8.27)μm, and(32.34±4.24) μm vs (15.52±5.92) μm, P <0.01].The gastric UI in the model therapy group were also lower than those in model control group respectively(13.8±6.5 vs 30.7±8.6, and 20.5±4.6 vs 35.6±9.5 , P <0.01). Conclusion Teprenone may have gastric mucosal protection effect in portal hypertensive rats.
出处
《中华消化杂志》
CAS
CSCD
北大核心
2004年第10期601-603,共3页
Chinese Journal of Digestion
